Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy

References

• Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999;29:1662–7.
   PubMed Web of Science ®Google Scholar
• Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–59.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52:3259–65.
   PubMed Web of Science ®Google Scholar
• Bao ZJ, Qiu DK, Ma X, Fan ZP, Zhang GS, Huang YQ, Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007;13:3003–8.
   PubMed Web of Science ®Google Scholar
• Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003;48:1622–6.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010;22:199–206.
   PubMed Web of Science ®Google Scholar
• Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009;16:605–11.
   PubMed Web of Science ®Google Scholar
• Fritz IB, Yue KT. Long-chain carnitine acyltransferase and the role of acylcarnitine derivatives in the catalytic increase of fatty acid oxidation induced by carnitine. J Lipid Res 1963;4:279–88.
   PubMed Web of Science ®Google Scholar
• Morris AJ, Carey EM. Postnatal changes in the concentration of carnitine and acylcarnitines in the rat brain. Brain Res 1983;284:381–4.
   PubMedGoogle Scholar
• Bremer J. Carnitine–metabolism and functions. Physiol Rev 1983;63:1420–80.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Pistone G, Astuto M, Dell'Arte S, Finocchiaro G, Lo Giudice E, L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003;21:271–5.
   PubMedGoogle Scholar
• Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008;53:3018–25.
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–6.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Cederblad G, Lindstedt S. A method for the determination of carnitine in the picomole range. Clin Chim Acta 1972;37:235–43.
   PubMed Web of Science ®Google Scholar
• Brass EP, Hoppel CL. Carnitine metabolism in the fasting rat. J Biol Chem 1978;253:2688–93.
   PubMed Web of Science ®Google Scholar
• Conn HO. A clinical hepatologist's predictions about non-absorbed carbohydrates for the early twenty-first century. Scand J Gastroenterol Suppl 1997;222:88–92.
   PubMedGoogle Scholar
• Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768–73.
   PubMed Web of Science ®Google Scholar
• Reitan RM, Wolfson D. The Halstead-Reitan: neuropsychological test battery: theory and clinical interpretation. Tucson, Az: Neuropsychology Press; 1993.
   Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
   PubMed Web of Science ®Google Scholar
• Beck A, Steer R, Garbin M. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:122–32.
   Google Scholar
• Spielberger CD, Gorsuch RL, Lushene RE. Test manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press; 1970.
   Google Scholar
• Van Der Rijt CC, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol 1984;57:423–6.
   PubMedGoogle Scholar
• Opolon P, Rapin JR, Huguet C, Granger A, Delorme ML, Boschat M, Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (Pam) hemodialysis (Hd). Trans Am Soc Artif Intern Organs 1976;22:701–10.
   PubMedGoogle Scholar
• Pugh RN, Murray-Lyon LM, Dawson JL, Petroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9.
   PubMed Web of Science ®Google Scholar
• Da Fonseca-Wollheim F. Direkte plasmaammoniakbestimmung ohne Enteiweissung. Z Klin Chem Biochem 1973;11:426–31.
   PubMedGoogle Scholar
• Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45–9.
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Boza F, García-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001;96:2718–23.
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005;41:790–800.
   PubMed Web of Science ®Google Scholar
• Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci 2008;53:1114–21.
   PubMed Web of Science ®Google Scholar
• Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology 2003;47:94–7.
   PubMedGoogle Scholar
• Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L, Astuto M, Vecchio I, Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol 2009;21:762–70.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 2006;51:2242–7.
   PubMed Web of Science ®Google Scholar
• Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005;20:359–67.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 2007;86:1738–44.
   PubMedGoogle Scholar
• Shores NJ, Keeffe EB. Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci 2008;53:2330–3.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005;11:7197–202.
   PubMed Web of Science ®Google Scholar
• Handelman GJ. Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. Blood Purif 2006;24:140–2.
   PubMedGoogle Scholar
• Zammit VA, Ramsay RR, Bonomini M, Arduini A. Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev 2009;61:1353–62.
   PubMed Web of Science ®Google Scholar
• Llansola M, Erceg S, Hernández-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis 2002;17:389–97.
   PubMedGoogle Scholar
• Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006;114:1–7.
   PubMed Web of Science ®Google Scholar
• Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988;451:205–12.
   PubMed Web of Science ®Google Scholar
• Hoang BX, Graeme Shaw D, Pham P, Levine S. Restoration of cellular energetic balance with L-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment. Med Hypotheses 2007;69:262–72.
   PubMedGoogle Scholar
• Sharma P. Minimal hepatic encephalopathy. J Assoc Physicians India 2009;57:760–3.
   PubMedGoogle Scholar
• Cagnon L, Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res Rev 2007;56:183–97.
   PubMedGoogle Scholar
• Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2011;93:1–10.
   PubMedGoogle Scholar
• Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009;89:71–6.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Li Volti G, Galvano F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 2009;58:1618–23.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338–45.
   PubMed Web of Science ®Google Scholar